# Lupin Receives US FDA Approval for Simvastatin Tablets

| BSE : 500257 | NSE: Lupin | REUTERS: LUPN.BO | BLOOMBERG: LPC IN |
|---|---|---|---|

**Mumbai, 15 May 2007**: Lupin Ltd., announced today that it has received final approval from the US FDA for it's Abbreviated New Drug Application (ANDA) for Simvastatin Tablets 10mg, 20mg, 40mg and 80mg.

Lupin's Simvastatin Tablets are the AB-rated generic equivalent of Merck's Zocor® tablets. Simvastatin is indicated for the treatment of high cholesterol.

"The approval of our Simvastatin ANDA marks our entry in the finished dosages market for the widely prescribed class of lipid modifying drugs. The launch of Simvastatin will further expand our generic portfolio," said Dr. Kamal Sharma, Managing Director, Lupin.

With this approval, Lupin now has 21 ANDAs approved by the US FDA.

**About Lupin**
Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with strong research focus. It has a programme for developing New Chemical Entities. The Company has state-of-the-art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDS and Asthma.

For the financial year ended March 2007, Lupin's Revenues and Profit after Tax were Rs.20,289 million (US$ 475 million) and Rs. 3,021 million (US$ 70 million) respectively.

**For further information contact:**
Raju Kane
The Source
Tel. +91 22 24901327/28
Telefax: +91 22 24901325
Mobile: +91 98200 45656
E-mail: rajukane@sourcepr.com